Jagadish Puppala, MD
Cardiovascular Disease · Grapevine, TXNPI 1841292489
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. 2023 is the largest year on record at $206, 2.1 times the $98 reported in 2019. That places this record below the midpoint for cardiovascular disease clinicians in TX, where the typical reported total is $3,258.
Across 25 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$119
- Merck$107
- Novo Nordisk$93
- Johnson & Johnson$92
- Boehringer Ingelheim$72
- Boston Scientific$20
- plus $37 from 2 others
What the payments were for
- Food & beverage$540100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 6 | $119 |
| Merck | 6 | $107 |
| Novo Nordisk | 1 | $93 |
| Johnson & Johnson | 5 | $92 |
| Boehringer Ingelheim | 4 | $72 |
| Boston Scientific | 1 | $20 |
| Pfizer | 1 | $19 |
| Novartis | 1 | $18 |
How this compares
$540 in reported general payments places this provider in the 20th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 332 | $241,935 |
| XareltoRivaroxaban | 72 | $71,638 |
| EntrestoSacubitril/Valsartan | 20 | $22,283 |
| Repatha SureclickEvolocumab | 17 | $8,591 |
| JardianceEmpagliflozin | 13 | $7,539 |
| Potassium Chloride | 285 | $5,389 |
| Ranolazine ErRanolazine | 47 | $4,597 |
| Metoprolol Succinate | 271 | $3,424 |
| Amiodarone Hcl | 86 | $2,952 |
| ClopidogrelClopidogrel Bisulfate | 281 | $2,747 |
| Atorvastatin Calcium | 259 | $2,603 |
| Metoprolol Tartrate | 256 | $1,657 |
| Furosemide | 303 | $1,517 |
| Losartan Potassium | 131 | $1,415 |
| Nifedipine ErNifedipine | 62 | $1,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $19 | $241,935332 claims |
| Johnson & JohnsonXarelto | $92 | $71,63872 claims |
| NovartisEntresto | $18 | $22,28320 claims |
| Boehringer IngelheimJardiance | $72 | $7,53913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Grapevine
- John OsborneGrapevine$1.3M
- Vikas JainGrapevine$261K
- Paul BhellaGrapevine$194K
- Ramin Farzaneh-FarDallas$17.1M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.